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Background: Cardiovascular disease is prevalent and frequently unrecognized in patients with chronic obstructive
pulmonary disease (COPD). NT-proBNP is an established risk factor in patients with heart failure. NT-proBNP may
also be released from the right ventricle. Thus serum NT-proBNP may be elevated during acute exacerbations
of COPD (AECOPD). The prognostic value of NT-proBNP in patients hospitalized with AECOPD is sparsely
studied. Our objective was to test the hypothesis that NT-proBNP independently predicts long term mortality
following AECOPD.
Methods: A prospective cohort study of 99 patients with 217 admissions with AECOPD. Clinical,
electrocardiographic, radiological and biochemical data were collected at index and repeat admissions and
analyzed in an extended survival analysis with time-dependent covariables.
Results: Median follow-up time was 1.9 years, and 57 patients died during follow-up. NT-proBNP tertile limits
were 264.4 and 909 pg/mL, and NT-proBNP in tertiles 1 through 3 was associated with mortality rates of 8.6,
35 and 62 per 100 patient-years, respectively (age-adjusted log-rank p<0.0001). After adjustment for age, gender,
peripheral edema, cephalization and cTnT in a multivariable survival model, the corresponding hazard ratios for
dying were 2.4 (0.95-6.0) and 3.2 (1.3-8.1) (with 95% confidence intervals in parentheses, p-value for trend 0.013).
Conclusions: NT-proBNP is a strong and independent determinant of mortality after AECOPD.
Keywords: Chronic obstructive pulmonary disease, Heart failure, NT-proBNP, MortalityBackground
Comorbidities are important determinants of outcome
and quality of life of patients with chronic obstructive
pulmonary disease (COPD) [1]. The extrapulmonary
manifestations of COPD include cardiovascular diseases
such as cerebral stroke, myocardial infarction (MI), heart
failure, and cardiac arrhythmias. These conditions are
more common among COPD patients than in the gen-
eral population, also after adjusting for smoking and
other important confounders [2-6]. Moreover, heart dis-
ease often remains undiagnosed in these patients [7-10].
This may in part be because the symptoms and signs of
MI and heart failure may mimic an acute exacerbation* Correspondence: a.d.hoiseth@medisin.uio.no
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reproduction in any medium, provided the orof COPD (AECOPD), but also because the classic symp-
tom and sign of MI, i.e. chest pain and ECG changes,
are poorly associated with myocardial injury during
AECOPD [11-13]. Using a highly sensitive assay, we
have previously shown that nearly three quarters of
patients admitted with AECOPD have cardiac troponin
T (cTnT) above the 99th percentile (14 ng/L), and that
even modest elevation is associated with increased
mortality [14,15].
The cardiac peptides B-type natriuretic peptide (BNP)
and the N-terminal fragment of its prohormone pro-
BNP, i.e. NT-proBNP, are both established biomarkers of
heart failure, [16] and are primarily used for diagnosis,
risk stratification and management of heart failure. The
natriuretic peptides (NP) have, however, also been
shown to be elevated in patients with COPD without
known heart failure [9,15,17]. It has been proposed thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this setting [17,18]. Cor pulmonale, secondary pulmon-
ary hypertension, or hypoxemia may represent important
stimuli for the release of NP from the right heart. In
stable COPD patients, increased concentration of a NP
seems to be associated with poorer long-term survival,
[19-22] although this finding not always is reproduced
[23]. In one study of 140 stable COPD patients recruited
at an outpatient clinic, NT-proBNP levels were asso-
ciated with mortality in unadjusted analysis, but not
after adjustment for echocardiographic variables, sug-
gesting that underlying heart disease may be the cause
of both increased NT-proBNP and mortality [21].
During AECOPD the NP levels are higher than in the
stable state, [18,23,24] and the stimuli for their release
may be more complex. Three papers addressing NP as
prognostic markers after AECOPD do not conclude uni-
formly, [15,17,18] as only Medina found significant asso-
ciation with long-term mortality. Consequently, it
remains unresolved whether circulating natriuretic pep-
tides measured during AECOPD provide independent
long-term prognostic information. Moreover, the poten-
tial incremental prognostic value of combining cardiac
troponins, using contemporary high sensitivity assays,
and NP still remains unresolved. The release of the two
biomarkers may in part be due to the same mechanisms,
but their levels during exacerbations have shown con-
flicting degrees of correlation [15,25]. In a single study
only have both NT-proBNP and cTnT during AECOPD
been measured and related to survival [15]. cTnT, mea-
sured by a former generation assay, and NT-proBNP
above the upper limits of normal were both associated
with increased 30 days mortality, but not with 12 month
mortality. Further, while NT-proBNP elevation provided
incremental prognostic information to cTnT, the con-
verse was not true.
We hypothesized that the concentrations of NT-
proBNP and cTnT on admission for exacerbation of
AECOPD, as measured by a highly sensitive assay (hs-




During 23 months in 2005 and 2006, all patients admit-
ted with AECOPD were eligible for inclusion in this pro-
spective cohort study. If patients had more than one
admission during the inclusion period, data from all
admissions were recorded and used in the analyses, as
described in the statistics section. On each admission we
recorded clinical data, ECGs, chest radiographs, and
results from blood analyses. The clinical data recorded
were heart rate, blood pressure, body temperature,
respiratory rate, arterial blood gases (pH, PaCO2, PaO2),arterial oxygen saturation (SaO2), wheezing, chest pain,
and the use of accessory muscles of respiration. ECGs
were analyzed for the presence of P pulmonale, QRS axis
deviation, signs of acute ischemia (ST-segment depres-
sion or elevation), and previous MI (T-wave inversion,
pathological Q-wave, loss of R, or left bundle branch
block, and by using the cardiac infarction injury score
(CIIS), where a score ≥20 indicates high probability of
prior MI) [26]. Two independent investigators, who were
blinded to all clinical data, conducted the ECG analyses.
Differences were settled by consensus regarding the
qualitative analyses, and by a third investigator regarding
CIIS (when the two initial scorings were on opposite
sides of 20). Two blinded investigators examined the
radiographs for the presence of cephalization of the lung
veins, infiltrates, cardiomegaly, or pleural effusions.
Haemoglobin, leucocyte, neutrophil and platelet
counts, electrolytes, blood glucose, and serum CRP were
recorded from the hospital records. Serum and plasma
from blood drawn on admission were stored at −80°C
for subsequent analysis of creatinine, hs-cTnT and NT-
proBNP (Roche Diagnostics, Mannheim, Germany). The
NT-proNBP assay has a lower limit of detection of
5.0 pg/mL. The coefficients of variation are reported to
be 4.2%, 2.4% and 1.3% at concentrations of 44 pg/mL,
126 pg/mL and 2410 pg/mL, respectively. Body mass
index (BMI) and spirometry during stable phase were
recorded when available. Medical history was obtained
by patient interview and by retrieving information from
hospital records. Patients were categorized as current,
former or never smokers. We also recorded the number
of admissions with AECOPD during the 12 months
prior to inclusion. The endpoint was length of survival
after the initial admission, with end of follow-up on
December 31st 2008. Survival status and dates of death
were retrieved from the National Population Registry.
All included patients gave written informed consent.
The study protocol was approved by the Data Inspector-
ate and by the Regional Committee for Research Ethics.
Additional information regarding the inclusion proced-
ure and the study population is available in the add-
itional material [see Additional file 1] and an earlier
paper [14].
Statistical analyses
First, NT-proBNP was categorized by tertiles, and the
mortality rates between the NT-proBNP tertiles were
compared using age-adjusted log-rank test. Investigation
of potential confounding was done in two steps: First by
identifying variables associated with NT-proBNP, and
then by analyzing which of these that were also asso-
ciated with mortality. Univariable baseline associations
between NT-proBNP tertiles and covariables were ana-
lyzed using Chi-square or Fisher’s exact test for
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tinuous variables. Then, for the covariables that were
associated with NT-proBNP with a p-value<0.20, we
investigated the association between the corresponding
covariable and mortality using an age-adjusted log-rank
test. In this analysis, continuous variables were categor-
ized: Number of admissions during the past year was
categorized as 0, 1 or ≥2, as in the ECLIPSE study [27].
hs-cTnT was categorized into three groups according to
cut-offs at 14 and 40 ng/L, as these cut-offs have shown
to discriminate well with regard to survival [14]. The
remaining continuous covariables were dichotomized at
pre-specified limits: FEV1/FVC at the mean (0.45), BMI
at the lower limit of normal (20 kg/m2), CRP at 50 mg/L,
and creatinine at 100 μmol/L.
The variables associated with both NT-proBNP and
mortality (p<0.20 in both tests above) were included
in a multivariable survival analysis. For these variables,
we also investigated potential effect modification and
tested for homogeneity using Mantel-Haenszel test
[28]. If this indicated effect modification of the asso-
ciation between NT-proBNP and mortality, a product-
term between NT-proBNP and the corresponding
covariable was included in the initial multivariable sur-
vival model. If the product-term proved significant with
p-value<0.05, the covariable in question was considered
an effect modifier.
Up until this point, only the index observations were
used, but for the final survival analysis, we used an
extended Cox regression analysis with time-dependent
covariables, [29] such that covariables that may change
between admissions (i.e. all covariables except age at in-
clusion, gender, lung function, BMI, and medical history)
were updated at each subsequent admission. Using a
backward elimination procedure, the model was reduced
by removing variables with p-values >0.05 provided that
the coefficient of the association between mortality and
NT-proBNP changed less than 20%. Age and gender
were kept in the model by convention. Finally, the inter-
action terms between NT-proBNP and age, gender, and
creatinine were added to the model to check whether
important interactions had been overlooked.
We performed four supplementary survival analyses:
i) The described analysis restricted to the patients with
no history of heart failure, ii) with NT-proBNP as a
continuous variable (log-transformed; lnBNP), iii) with
NT-proBNP categorized at 1000 and 2500 pg/mL, as
suggested by Abroug et al., [30] and iv) the described
analysis restricted to patients without chest pain or ECG
changes indicative of acute ischemia (i.e. patients that
may fulfill the criteria for an MI).
The proportional hazards assumption was checked by
the Martingale residuals on standard Cox regression
models using the index observations only. Analyses ofeffect modification were done using STATA 10 (Stata
Corp LP, TX, USA). All other analyses were done using
SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
99 patients were included. Mean age at inclusion was
71.5 years (standard deviation (SD) 9.0 years), and 47
(47%) were female. Spirometry measurement from the
stable state was available in 88 patients. Mean FEV1
was 0.91 liter (SD 0.45 liter), and mean FEV1/FVC was
45.3% (SD 14.2%). Median NT-proBNP concentration at
inclusion was 423.3 pg/mL, and the tertile limits were
264.4 and 909 pg/mL. 41 patients were readmitted dur-
ing the inclusion period, adding to a total of 219 admis-
sions. In 217 of these, we had NT-proBNP measured,
with a median of 560.4 pg/mL. Among the patients with
more than one NT-proBNP measurement, the median
change (absolute value) from the previous measurement
was 66% (IQR 41-150%). Three patients had two con-
secutive NT-proBNP measurements less than 5% apart,
but none of these changed tertiles. The prevalence of
categorical variables and the mean of continuous vari-
ables in each tertile of NT-proBNP at inclusion are
reported in Table 1 for those variables associated with
NT-proBNP (p<0.20). Among the variables not asso-
ciated with NT-proBNP were: a history of coronary ar-
tery disease (27%), arterial hypertension (31%), smoking
status (48% current smokers), chest pain on admission
(10%), kidney function (mean creatinine 76 μg/L), P pul-
monale (25%), right axis deviation (10%), atrial fibrilla-
tion (7%), prior MI (40%), and ischemia in ECG (27%).
Median NT-proBNP concentrations (with interquartile
range) among patients with 0, 1 and ≥2 admissions the
past 12 months were 339 (183–1054), 679 (154–1438)
and 421 (157–1389) pg/mL, respectively (p=0.826).
The correlation between NT-proBNP and hs-cTnT was
moderate (both logarithmically transformed, Pearson
rho=0.34, p=0.0006).
During a median follow-up of 1.9 years, 57 (58%)
patients died, with an overall mortality rate of 28.7 per
100 patient-years. NT-proBNP tertiles on inclusion were
associated with increasing mortality rates, i.e. 8.6 (95%
confidence interval 4.3-17), 35 (23–54) and 62 (43–91)
per 100 patient-years, respectively (Figure 1, age-adjusted
log-rank p-value<0.0001). When applying the cut-offs
suggested by Abroug, [30] the mortality rates were 19,
25 and 120 per 100 patient-years among patients with
NT-proBNP <1000, 1000–2500 and ≥2500 pg/mL,
respectively (age-adjusted log-rank p-value<0.0001).
Of the variables that were associated with NT-proBNP
concentrations, history of diabetes and lung function
failed to show any association with mortality and were
therefore not included in further analyses. For the
remaining covariables, stratified analyses of mortality








Female, n (%) 16 (48) 18 (55) 13 (39) 0.463
Age (years) , mean (SD) 66.0 (7.4) 71.9 (8.2) 76.6 (8.1) <0.0001
BMI (kg/m2), mean (SD) 23.2 (5.3) 23.6 (6.1) 21.3 (3.9) 0.149
Medical history
FEV1/FVC, mean (SD)
* 0.46 (0.16) 0.45 (0.14) 0.46 (0.13) 0.943
FEV1 (L), mean (SD)
* 0.99 (0.55) 0.81 (0.36) 0.94 (0.39) 0.305
FEV1 (% of pred.), mean (SD)* 33 (18) 31 (20) 36 (20) 0.375
Heart failure, n (%) 3 (9.1) 4 (12) 7 (21) 0.445
Diabetes Mellitus, n (%) 3 (9.1) 5 (15) 0 0.008
Atrial fibrillation, n (%) 1 (3.0) 3 (9.1) 6 (18) 0.149
Admissions past 12 months 0.814
0 13 (35) 14 (38) 10 (27)
1 8 (31) 7 (27) 11 (42)
≥2 12 (33) 12 (33) 12 (33)
Findings on admission
Peripheral edema, n (%) 3 (9.1) 6 (18) 9 (27) 0.179
Cephalization, n (%) 2 (6.1) 3 (9.1) 11 (33) 0.007
SaO2 (%), mean (SD) 92.1 (3.0) 89.0 (6.8) 88.1 (9.0) 0.177
Biochemistry
CRP (mg/L), median (IQR) 20 (2.0-35) 38 (17–71) 54 (2.0-84) 0.071
hs-cTnT (ng/L), median (IQR) 14 (8.3-26) 31 (15–41) 44 (22–58) 0.0006
Creatinine (μmol/L), median (IQR) 64 (55–79) 65 (53–89) 75 (60–91) 0.213
The table includes variables associated with NT-proBNP tertiles (p<0.20) with past admissions, lung and kidney function added to better characterize the cohort.
* Spirometry available in 88 patients (n=28, 28 and 29 in tertiles 1–3). SD, standard deviation; IQR, interquartile range; BMI, body mass index; CRP, C-reactive
protein; hs-cTnT, high-sensitivity cardiac troponin T.
N=99 unless otherwise specified.
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(Table 2). Mantel-Haenszel tests showed no statistically
significant effect modification of the association between
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Figure 1 Mortality after acute exacerbation of COPD stratified
by level of NT-proBNP. Based on 217 admissions and 57
mortalities in 99 patients.listed in Table 2, and the following variables were
included in the initial multivariable model: age, gender,
BMI, history of heart failure, atrial fibrillation on admis-
sion, peripheral edema, cephalization of the lung veins,
CRP, and hs-cTnT. Reduction of the model gave the final
model in Table 3, showing increasing mortality with
increasing levels of NT-proBNP (p =0.013 for trend). hs-
cTnT, gender, peripheral edema, and cephalization of
the lung veins were also independently associated with
mortality. None of the interaction terms investigated
proved statistically significant (p-values >0.05). Using the
natural logarithm of the NT-proBNP concentration
(lnBNP) as a continuous variable in the final model
showed a hazard ratio of 1.5 (95% CI: 1.2-1.9, p=0.0005)
per unit increase in lnBNP. By adhering to the model
reduction described, BMI and CRP were eliminated from
the model both when analyzed as continuous and dicho-
tomized variables. Similarly, analyzing hs-cTnT continu-
ously and categorized made no noteworthy change
in the model. Patients with a history of heart failure had
non-significantly higher NT-proBNP concentrations
(median 1554 vs. 400 pg/mL, p=0.102), and when
Table 2 Mortality (m), mortality rate (MR, per 100 patient-years) in NT-proBNP tertiles, and mortality rate ratio per
tertile increase in NT-proNBP








m (MR) m (MR) m (MR)
Gender 2.4 (1.8-3.3)
Female 6 (16.5) 12 (35) 12 (67) 2.1 (1.3-3.3)
Male 1 (1.9) 8 (39) 18 (51) 2.8 (1.8-4.2)
Age, years 2.3 (1.6-3.2)
<65 1 (5.4) 1 (70) 1 (15) 1.8 (0.49-6.8)
65-74 5 (7.9) 11 (33) 10 (65) 3.3 (1.9-5.6)
≥75 1 (11) 8 (39) 19 (60) 1.7 (1.0-2.8)
BMI, kg/m2 2.3 (1.7-3.2)
<20 2 (9.6) 8 (45) 11 (64) 2.1 (1.2-3.5)
≥20 5 (7.2) 9 (30) 18 (50) 2.5 (1.6-3.7)
History of DM 2.4 (1.7-3.2)
No 6 (7.6) 16 (33) 29 (57) 2.4 (1.7-3.3)
Yes 1 (8.8) 4 (21) 1 (44) 2.6 (0.8-8.4)
Cephalization 2.0 (1.4-2.7)
No 7 (8.0) 19 (37) 13 (31) 1.9 (1.3-2.8)
Yes 0 1 (30) 17 (150) 2.2 (1.2-4.2)
Atrial fibrillation 2.3 (1.7-3.1)
No 7 (8.0) 19 (36) 24 (50) 2.3 (1.6-3.2)
Yes 0 1 (41) 6 (109) 2.3 (0.95-5.6)
Peripheral edema 2.3 (1.7-3.1)
No 5 (6.4) 15 (32) 17 (38) 2.2 (1.5-3.2)
Yes 2 (17) 5 (68) 13 (146) 2.4 (1.5-4.1)
SaO2 <90% 2.3 (1.7-3.1)
No 5 (6.8) 12 (33) 17 (50) 2.5 (1.7-3.8)
Yes 2 (12) 8 (42) 13 (68) 1.9 (1.2-3.2)
CRP, mg/L 2.4 (1.7-3.2)
<50 6 (8.2) 13 (50) 13 (38) 2.0 (1.4-3.1)
≥50 1 (6.0) 7 (24) 17 (90) 3.0 (1.8-5.1)
hs-cTnT, ng/L 1.8 (1.3-2.5)
<14 2 (4.3) 1 (10) 0 0.83 (0.18-3.9)
14-40 4 (12) 10 (30) 10 (71) 2.5 (1.5-4.4)
≥40 1 (10) 9 (78) 20 (67) 1.5 (0.94-2.3)
All, crude MRR 7 (7.8) 20 (36) 30 (56) 2.4 (1.7-3.2)
Based on 217 admissions and 57 mortalities among 99 patients. Mortality rate ratio expressed as score test for trend for a one tertile increase in NT-proNBP
*Adjusted for the corresponding covariable. BMI, body mass index; DM, diabetes mellitus; CRP, C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T.
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of heart failure, the associations with mortality remained
practically unchanged (Table 3). At the index admission,
patients with (n=35) and without (n=64) chest pain or
ECG signs of acute ischemia had median NT-proBNP
concentrations 655 (IQR 197–1311) and 345 (IQR 145–
1312) pg/mL, respectively (p-value 0.219). When
restricting the analysis to admissions without chest pain
or ST-T changes, the association between cTnT andmortality increased markedly while the association be-
tween NT-proBNP and mortality was moderately attenu-
ated and was no longer statically significant (Table 3).
None of the models violated the proportional hazards
assumption.
Discussion
The new and important findings of the current study are
that higher levels of NT-proBNP during AECOPD are
Table 3 Hazard ratios for dying after admission for acute exacerbation of COPD
Variable All patients* Patients with no history of
heart failure†
Patients with no chest pain
or ischemia‡










Age, per 5 years 1.3 (1.08-1.5) 0.003 0.99 (0.83-1.2) 0.872 0.95 (0.78-1.2) 0.643 0.98 (0.75-1.3) 0.860
Female 1.4 (0.81-2.3) 0.252 2.0 (1.1-3.6) 0.020 1.7 (0.87-3.3) 0.119 2.8 (1.2-6.8) 0.020
Peripheral edema 3.2 (1.9-5.5) <0.0001 2.1 (1.2-3.8) 0.014 2.1 (1.0-4.2) 0.044 2.6 (1.1-6.1) 0.032
Cephalization 4.5 (2.5-8.0) <0.0001 2.2 (1.2-4.2) 0.014 2.2 (1.0-4.8) 0.049 3.4 (1.2-9.8) 0.022








<14 1 1 1 1
14-40 6.3 (1.9-21) 0.003 4.3 (1.2-15) 0.024 4.5 (1.3-16) 0.021 9.4 (1.2-77) 0.036
≥40 12 (3.5-38) <0.0001 6.5 (1.8-24) 0.005 6.4 (1.7-24) 0.007 16 (1.7-140) 0.013








1(< 264.4 pg/mL) 1 1 1 1
2 (264.4-909 pg/mL) 4.3 (1.8-10) 0.0009 2.4 (0.95-6.0) 0.064 2.7 (1.0-7.4) 0.049 2.1 (0.60-7.5) 0.247
3 (≥ 909 pg/mL) 6.9 (3.0-16) <0.0001 3.2 (1.3-8.1) 0.012 3.3 (1.2-9.1) 0.023 2.5 (0.59-9.0) 0.167
*Based on 217 admissions and 57 mortalities among 99 patients in an extended Cox analysis with time dependent covariables. †Based on 185 admissions among
85 patients (46 mortalities). ‡Based on 137 admissions among 64 patients (30 mortalities). hs-cTnT, high-sensitivity cardiac troponin T.
Høiseth et al. Respiratory Research 2012, 13:97 Page 6 of 9
http://respiratory-research.com/content/13/1/97associated with increased long-term mortality, and that
this association is independent of important clinical,
radiographic, pulmonary function, and biochemical, vari-
ables, including cTnT. Although we observed a moder-
ately strong association between NT-proBNP and cTnT,
NT-proBNP provided prognostic information above and
beyond cTnT.
The prevailing view is that the primary stimulus for
NT-proBNP release is myocardial strain in the face of
increased right or left ventricular filling pressures
[31,32]. Additionally, it has been shown that hypoxia sti-
mulates the natriuretic peptide system [33]. Of these,
both hypoxia and increased pressure in the right heart
may be present in COPD, both in stable state and during
exacerbations. Although there was a trend against higher
concentrations of NT-proBNP with lower SaO2, this
association was not statistically significant. In the
absence of echocardiograms, we analyzed ECGs for
signs of right ventricular hypertrophy/pressure overload,
but found no association with NT-proBNP level. Moreover,
the association between NT-proBNP and mortality was
present also when adjusting for peripheral edema, a clinical
feature of elevated right ventricular filling pressures and
for decades known as a strong predictor of mortality in
COPD. [34] Several studies have shown that left heart
failure is relatively common in COPD patients, [2-4,9,35,36]
and we find it reasonable to assume that this contributes
to the release of NT-proBNP during AECOPD.
Guidelines provide cut-offs to rule heart failure in or
out in stable patients. Attempts have been made to make
similar decision limits in the acute setting, [30,37,38] butthe grey zone is wide, and such recommendations have
not been incorporated in the guidelines. Therefore, in
the absence of established cut-offs in the acute setting,
we chose to explore the data by analyzing NT-proBNP
both as a continuous and categorical variable, categor-
ized by tertiles in the main analysis. Categorization by
NT-proBNP concentrations of 1000 and 2500 pg/mL,
as suggested by Abroug, [30] also discriminated well.
However, we found that a lower cut-off also provided
prognostic information, with the lower tertile in our
material not being far from the limit to rule heart failure
very improbable in the PRIDE algorithm (264.4 and
300 pg/mL, respectively) [37]. We found an association
between NT-proBNP concentrations and mortality with
both categorizations, as well as analyzed as a logarith-
mically transformed continuous variable. The association
between NT-proBNP tertiles and mortality remained
practically unchanged when restricting the analysis to
patients with no known history of heart failure, and it is
not unlikely that unrecognized left heart failure contri-
butes to the mortality in AECOPD. In our study, 24% of
NT-proBNP measurements were above 1800 pg/mL,
and 18% were above 2500 pg/mL, indicating a high
probability of concomitant left heart failure in one of
four to one of five AECOPD admissions [30,37]. The
corresponding proportions were 18% and 12% after
excluding patients with a history of heart failure.
We found cTnT to be more strongly associated with
mortality than NT-proBNP. The pathobiology underlying
troponin release is multifaceted. Recently, six potential
mechanisms of troponin release have been proposed
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Three alternative mechanisms are cellular release of
proteolytic troponin degradation products, increased cel-
lular wall permeability with the release of intact cardiac
troponin, and active secretion of vesicles containing car-
diac troponin. These may occur during AECOPD, with
increased wall stress and hypoxemia, factors that also
stimulate the production and release of NT-proBNP. If
that were the case, we would expect some degree of
correlation between hs-cTnT and NT-proBNP. In previ-
ous studies, correlations between NT-proBNP and cTnT,
and between BNP and cTnI have been found to be
r=0.46 (p<0.001) and r=0.006 (p=0.438), respectively,
during AECOPD [15,25]. Different study design as well
as different proteins being measured may explain these
diverging results. In the present study, the correlation
coefficient between hs-cTnT and NT-proBNP (both log-
transformed) was 0.34, and the association between hs-
cTnT and mortality, as previously published, [14] did
not change notably when we took NT-proBNP into
account, suggesting a relative pathobiological independ-
ence between these biomarkers.
When excluding patients with ischemic ST-T changes
or chest pain, the association between NT-proBNP and
mortality was moderately attenuated and no longer
significant (Table 3, two rightmost columns). This may
be partly due to reduced statistical power. However,
the point estimate for the strength of the association
also was reduced, which suggests that the association be-
tween NT-proBNP and mortality was stronger among
patients with signs or symptoms of myocardial ischemia.
Because of the limited power and the retrospective
nature of these analyses, these observations should be
interpreted with caution.
Our findings that NT-proBNP and cTnT are inde-
pendent predictors of mortality, are in accordance with
recent observations in both patients with chronic heart
failure and stable coronary artery disease, [40,41] as well
as in the general population, [42,43] demonstrating that
NT-proBNP and cTnT measured with a sensitive assay
provide complementary prognostic information. This
has not previously been shown in an AECOPD cohort:
Medina et al. found 3.9 times increased 1-year mortality
in patients with NT-proBNP>459.9 pg/mL, but did not
analyze troponin [17]. Chang et al. investigated cTnT
(using a conventional assay) and NT-proBNP with
regard to mortality after AECOPD, and found that either
biomarker above the upper limit of normal was asso-
ciated with increased 30 days mortality, but not with 12
month mortality [15]. The 1-year mortality in Chang’s
study was 18% compared to 30% in the present study.
We also report a higher mortality rate than Stolz et al.,
who observed a 22% mortality rate after 2 years of
follow-up and no significant association between BNPand long-term mortality [18]. That we found higher
overall mortality may in part explain why we found sig-
nificant differences also in long-term survival. Moreover,
we have included data from repeat admissions in our
analysis. It is possible that we have registered some
important events during follow-up that were missed by
the previous studies. The reasons for the lower sur-
vival in our study than in those of Stolz and Chang are
uncertain. The age, gender composition, lung function,
comorbidities and status on admission appear to be
comparable across the studies, and do not explain the
survival differences. Our unselected cohort may be more
representative of “real life” patients as we did not
exclude patients with AECOPD and radiological infil-
trates (11%), and this is likely to explain part of the differ-
ences in survival. The mortality in our study is within the
range that is reported in a 2009 review on COPD exacer-
bation [44]. In contrast to the report by Chang et al., we
found that cTnT, even in modest concentrations, is more
strongly associated with mortality than is NT-proBNP.
The survival analysis was done by using an extended
Cox regression model with time-dependent covariables.
The model is not widely used, but is well described in
standard textbooks on survival analysis [29,45]. Import-
antly, compared to a standard Cox regression model,
both the number of observations, the number of events
and the observation time is unchanged, so the data are
not inflated. Time is counted from inclusion until death
or censoring while variables that may vary between
admissions are updated at each admission. In our opin-
ion, such models generally reflect the true associations
between the recorded variables and the outcome more
accurately than standard models. And although these re-
peat recordings are incomplete (120 of 191 readmis-
sions), we have previously demonstrated that this model
has better fit than a model with baseline observations
only [14].
The term “frequent exacerbation phenotype” has been
introduced over the past years, and previous exacerba-
tion is the best predictor of future exacerbations [27].
As we included patients on admission for exacerbation,
it is likely that frequent exacerbators are overrepresented
in our material compared to a general COPD cohort.
We registered the number of exacerbations in the year
prior to inclusion to investigate if frequent exacerbations
were associated with NT-proBNP, but failed to find
such association (Table 1). Thus we do not believe that
exacerbation frequency bias the results of our analyses.
Among the weaknesses of this study is the relatively
low number of patients. Nevertheless, we have found
a strong and statistically significant association with a
clinically important endpoint. Thus, the sample size and
thereby the power of the study should be appropriate.
Moreover, when comparing our baseline data with those
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appears to be representative. Heart failure and pulmon-
ary embolism were not systematically investigated. This
would be of interest as it might contribute to troponin
release, NT-proBNP increase, and mortality. Echocardi-
ography would provide valuable data, but was beyond
the scope of the present study. We did not investigate
cause of death. Only four patients were autopsied, and
we believe that the cause of death as recorded on the
death certificates differentiates poorly between the rele-
vant diagnoses.
Conclusions
Increasing levels of NT-proBNP are independently asso-
ciated with long-term mortality after AECOPD, also
after multivariable adjustment including the level of
cTnT, cephalization on chest radiograph, peripheral
edema and gender. Unrecognized concomitant left heart
failure may contribute to the increased mortality.
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